CanariaBio Inc.

CanariaBio Inc. is a clinical-stage biotechnology company focused on the development of personalized immunotherapies for various cancers. The company's core technology platform utilizes mono-specific and multi-specific antibodies to stimulate the immune system to recognize and eliminate cancer cells. Its lead product candidate, Oregovomab, is a murine monoclonal antibody targeting the CA125 antigen, which is overexpressed in most epithelial ovarian cancers. The company was formed through a complex series of acquisitions involving OncoQuest Pharmaceuticals and the South Korean entity CanariaBio M (formerly Doosung Industrial). While the company has historically focused on late-stage clinical trials, it has recently faced significant regulatory and financial headwinds following disappointing results from its lead Phase 3 clinical program.